JP2005532256A5 - - Google Patents

Download PDF

Info

Publication number
JP2005532256A5
JP2005532256A5 JP2003543537A JP2003543537A JP2005532256A5 JP 2005532256 A5 JP2005532256 A5 JP 2005532256A5 JP 2003543537 A JP2003543537 A JP 2003543537A JP 2003543537 A JP2003543537 A JP 2003543537A JP 2005532256 A5 JP2005532256 A5 JP 2005532256A5
Authority
JP
Japan
Prior art keywords
lir
pharmaceutical composition
drug
agent
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003543537A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005532256A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/036372 external-priority patent/WO2003041650A2/en
Publication of JP2005532256A publication Critical patent/JP2005532256A/ja
Publication of JP2005532256A5 publication Critical patent/JP2005532256A5/ja
Pending legal-status Critical Current

Links

JP2003543537A 2001-11-14 2002-11-12 慢性関節リウマチを治療するためのlir機能の調節 Pending JP2005532256A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33589901P 2001-11-14 2001-11-14
PCT/US2002/036372 WO2003041650A2 (en) 2001-11-14 2002-11-12 Modulation of lir function to treat rheumatoid arthritis

Publications (2)

Publication Number Publication Date
JP2005532256A JP2005532256A (ja) 2005-10-27
JP2005532256A5 true JP2005532256A5 (enExample) 2006-01-12

Family

ID=30770813

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003543537A Pending JP2005532256A (ja) 2001-11-14 2002-11-12 慢性関節リウマチを治療するためのlir機能の調節

Country Status (8)

Country Link
US (1) US20050238643A1 (enExample)
EP (1) EP1453540A4 (enExample)
JP (1) JP2005532256A (enExample)
AU (1) AU2002360376B2 (enExample)
CA (1) CA2466118A1 (enExample)
MX (1) MXPA04004491A (enExample)
PL (1) PL374463A1 (enExample)
WO (1) WO2003041650A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006049215A1 (ja) * 2004-11-02 2006-05-11 Dainippon Sumitomo Pharma Co., Ltd. 自己免疫疾患を治療するための併用薬
GB0510627D0 (en) 2005-05-25 2005-06-29 Avidex Ltd Polypeptides
CA2611519A1 (en) 2005-06-17 2006-12-28 Tolerx, Inc. Ilt3 binding molecules and uses therefor
WO2008094176A2 (en) 2006-06-19 2008-08-07 Tolerx, Inc. Ilt3 binding molecules and uses therefor
CN102089327A (zh) * 2008-05-13 2011-06-08 健泰科生物技术公司 抗PirB抗体
WO2010101192A1 (ja) * 2009-03-03 2010-09-10 国立大学法人九州大学 関節リウマチまたはその関連疾患の予防または治療剤
EP2525822B1 (en) * 2010-01-20 2017-05-10 Merck Sharp & Dohme Corp. Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
CA2787783A1 (en) * 2010-01-20 2011-07-28 Tolerx, Inc. Anti-ilt5 antibodies and ilt5-binding antibody fragments
WO2014078956A1 (en) * 2012-11-20 2014-05-30 Revive Therapeutics Inc. The use of bucillamine in the treatment of gout
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗-ilt4抗體及抗原結合片段
JP7391868B2 (ja) 2017-12-22 2023-12-05 ジョウンセ セラピューティクス, インク. Lilrb2に対する抗体
AU2019302454A1 (en) 2018-07-09 2021-02-25 Bristol-Myers Squibb Company Antibodies binding to ILT4
WO2021160838A1 (en) * 2020-02-12 2021-08-19 Bioinvent International Ab Lilrb3 antibody molecules and uses thereof
IL297748A (en) 2020-05-01 2022-12-01 Ngm Biopharmaceuticals Inc ilt binding agents and methods of using them

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2278154A1 (en) * 1997-01-21 1998-07-23 Human Genome Sciences, Inc. Fc receptors and polypeptides
US6448035B1 (en) * 1997-04-24 2002-09-10 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR)
US6384203B1 (en) * 1999-05-12 2002-05-07 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
CA2398251A1 (en) * 2000-01-25 2001-08-02 Hyseq, Inc. Methods and materials relating to leukocyte immunoglobulin receptor-like (lir-like) polypeptides and polynucleotides

Similar Documents

Publication Publication Date Title
JP2005532256A5 (enExample)
US6232315B1 (en) Method for treating inflammatory diseases by administering a thrombin inhibitor
AU779292B2 (en) Treating sleep disorders using desloratadine
RU2007104095A (ru) Применение твердой пероральной дозировочной композиции пролонгированного действия для приготовления лекарственных средств
EP1569691A4 (en) DISTRIBUTION OF PHARMACEUTICAL AGENTS OVER THE HUMAN INSULIN RECEPTOR
JP2010500360A5 (enExample)
JP2007515469A5 (enExample)
JP2001019638A (ja) 高速吸収性液体組成物
JP2005533005A5 (enExample)
JP2005515966A5 (enExample)
DE60032749D1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
TW200621249A (en) Substituted amide beta secretase inhibitors
HUP0003705A2 (hu) Antiepilektikumokat tartalmazó fájdalomcsillapító készítmények és ilyen készítményeket alkalmazó eljárások
WO2006022996A3 (en) Dosage form containing multiple drugs
JP2002524529A5 (enExample)
JP2006515299A5 (enExample)
WO2003054018A3 (en) Anti-tirc7 antibodies in therapy of inflammatory diseases
EP1655026B1 (en) Solid pharmaceutical formulations comprising diacereine and meloxicam
JP2002326936A5 (enExample)
RU2007127127A (ru) 4-циклоалкил-замещенные производные тетрагидрохинолина и их применение в качестве лекарств
WO1991016896A1 (en) Pharmaceutical composition for use in treating pain
RU2004112422A (ru) Роувастатин в преддеменционных состояниях
WO2004032964A1 (ja) アレルギー性疾患治療剤
ES2356371T3 (es) Medicamentos terapéuticos para inducir tolerancia.